# T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

> **NCT00602693** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 41 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Multiple Myeloma
- Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** umbilical cord blood transplantation
- **DRUG:** Allopurinol
- **DRUG:** fludarabine phosphate
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total body irradiation
- **BIOLOGICAL:** Treg infusion
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT00602693
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-23
- **Primary completion:** 2014-09-25
- **Final completion:** 2015-04-16
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602693, "T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00602693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*